Privosegtor optic neuritis clinical trial design gains FDA agreement (Multiple Sclerosis News Today) - May 12, 2026 - "The FDA has formally agreed that the design and planned analysis of an upcoming Phase 3 trial testing privosegtor in people with optic neuritis could support a future application seeking the therapy’s approval if the trial succeeds...PIONEER-1 and PIONEER-2 are intended to support an approval application for optic neuritis....PIONEER-3, will evaluate the therapy in NAION, a condition in which the optic nerve is damaged due to reduced blood flow"
New P3 trial • Optic Neuritis
|